L&J Bio is committed to develop the therapeutic fusion proteins for neurodegenerative diseases through Dual Action Therapy (DAT) Platform. We have developed the innovative disease modifying therapy AL04 for Alzheimer's disease through the application of fusion protein and DAT platform to target both amyloid beta and hyper-phosphorylated tau aggregations. L&J Bio is planning to start phase 1 clinical trial 2025. L&J Bio is located both USA and Korea and will conduct clinical trial in US. AL04 is the fusion protein, consisting of HSA as a long-acting carrier, a blood-brain barrier (BBB) penetrable tandem-repeat cell-penetrating peptide and Cystatin C as the active moiety of drug. AL04 inhibits both amyloid beta (Aβ) deposition and hyperphosphorylated Tau aggregation in Tg2576 and JNPL3 mice. L&J Bio conducted pre-IND meeting with US FDA and conducting safety pharmacology toxicology study in Monkey. We are hoping to submit IND package in 2025 and start phase 1 study in US.